Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received for the settlement of litigation during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligationDueInNextTwelveMonths
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=lnth_ArbitrationWithPharmalucenceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) - USD ($)		1 Months Ended
	Oct. 31, 2019	Nov. 30, 2019	Dec. 31, 2019
Gain Contingencies [Line Items]
Minimum purchase commitments or payments under agreements			$ 0
Arbitration with Pharmalucence
Gain Contingencies [Line Items]
Total amount awarded	$ 3,500,000
Proceeds from litigation received		$ 3,500,000